Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 2/20 | 0.53 |
| ▸ | DTYMK | P23919 | 4/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27062361 | 1.00 | TERT (0.53) | TERTDTYMKF2POLBP2RY2 | |
| SCHEMBL26401791 | 1.00 | TERT (0.53) | TERTDTYMKF2POLBP2RY2 | |
| SCHEMBL27103942 | 1.00 | TERT (0.53) | TERTDTYMKF2POLBP2RY2 | |
| SCHEMBL26859999 | 1.00 | TERT (0.53) | TERTDTYMKF2POLBP2RY2 | |
| SCHEMBL27103969 | 1.00 | TERT (0.53) | TERTDTYMKF2POLBP2RY2 | |
| SCHEMBL25456890 | 1.00 | TERT (0.53) | TERTDTYMKF2POLBP2RY2 | |
| SCHEMBL16692051 | 1.00 | TERT (0.53) | TERTDTYMKF2POLBP2RY2 | |
| SCHEMBL17231693 | 1.00 | TERT (0.53) | TERTDTYMKF2POLBP2RY2 | |
| SCHEMBL27104050 | 1.00 | TERT (0.53) | TERTDTYMKF2POLBP2RY2 | |
| SCHEMBL27062376 | 1.00 | TERT (0.53) | TERTDTYMKF2POLBP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094261-A1 | COMPOSITIONS FOR MODULATING TAU EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9683235-B2 | Compositions for modulating Tau expression | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094261-A1 | COMPOSITIONS FOR MODULATING TAU EXPRESSION | MAPT, PSEN2, PSEN1 | TERT 636/4885DTYMK 867/4885F2 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.